{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:57:28Z","timestamp":1765961848858,"version":"3.41.2"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["J. pharm. pharm. sci."],"abstract":"<jats:p>Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and\/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes.<\/jats:p>","DOI":"10.3389\/jpps.2024.13193","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T04:11:25Z","timestamp":1723608685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy"],"prefix":"10.3389","volume":"27","author":[{"given":"Tanin","family":"Shafaati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshav","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/circresaha.116.308999","article-title":"Obesity, diabetes, and cardiovascular diseases","volume":"118","author":"Scherer","year":"2016","journal-title":"Circ Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.241.19.2035","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"J Am Med Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/diacare.2.2.120","article-title":"Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study","volume":"2","author":"Kannel","year":"1979","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/circresaha.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nrm2190","article-title":"Stressing the role of FoxO proteins in lifespan and disease","volume":"8","author":"van der Horst","year":"2007","journal-title":"Nat Rev Mol Cel Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-physiol-021909-135931","article-title":"The FoxO family in cardiac function and dysfunction","volume":"72","author":"Ronnebaum","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/jci60329","article-title":"Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice","volume":"122","author":"Battiprolu","year":"2012","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-016-0361-1","article-title":"Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy","volume":"15","author":"Kandula","year":"2016","journal-title":"Cardiovasc Diabetology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"The Am J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e396","DOI":"10.1161\/circulationaha.105.579268","article-title":"A clinician\u2019s guide to tissue Doppler imaging","volume":"113","author":"Ho","year":"2006","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"H733","DOI":"10.1152\/ajpheart.00339.2017","article-title":"Guidelines for measuring cardiac physiology in mice","volume":"314","author":"Lindsey","year":"2018","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diacare.24.1.5","article-title":"Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy","volume":"24","author":"Poirier","year":"2001","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ahj.2004.06.021","article-title":"Screening for heart disease in diabetic subjects","volume":"149","author":"Fang","year":"2005","journal-title":"Am Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1540-8175.2008.00690.x","article-title":"Is there any relationship between metabolic parameters and left ventricular functions in type 2 diabetic patients without evident heart disease?","volume":"25","author":"Yazici","year":"2008","journal-title":"Echocardiography"},{"key":"B17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"The Am J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get with the Guidelines-Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/circresaha.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"H176","DOI":"10.1152\/ajpheart.00058.2022","article-title":"Guidelines on models of diabetic heart disease","volume":"323","author":"Heather","year":"2022","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.ddmec.2010.08.001","article-title":"Diabetic cardiomyopathy: mechanisms and therapeutic targets","volume":"7","author":"Battiprolu","year":"2010","journal-title":"Drug Discov Today Dis Mech"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bbalip.2016.02.011","article-title":"Lipotoxicity in obesity and diabetes-related cardiac dysfunction","volume":"1861","author":"Zlobine","year":"2016","journal-title":"Biochim Biophys Acta (Bba) - Mol Cel Biol Lipids"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/circulationaha.108.792101","article-title":"Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart","volume":"119","author":"Boudina","year":"2009","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1161\/circresaha.117.311307","article-title":"Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial fission","volume":"122","author":"Tsushima","year":"2018","journal-title":"Circ Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/0092-8674(89)90133-5","article-title":"The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo","volume":"57","author":"Weigel","year":"1989","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0092-8674(90)90439-l","article-title":"The fork head domain: a novel DNA binding motif of eukaryotic transcription factors?","volume":"63","author":"Weigel","year":"1990","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/40194","article-title":"The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans","volume":"389","author":"Ogg","year":"1997","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/ng1193-230","article-title":"Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma","volume":"5","author":"Galili","year":"1993","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2174\/138945011796150307","article-title":"The complex biology of FOXO","volume":"12","author":"Monsalve","year":"2011","journal-title":"Curr Drug Targets"},{"key":"B30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrg2523","article-title":"The evolution of Fox genes and their role in development and disease","volume":"10","author":"Hannenhalli","year":"2009","journal-title":"Nat Rev Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/db11-0548","article-title":"FoxO6 integrates insulin signaling with gluconeogenesis in the liver","volume":"60","author":"Kim","year":"2011","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/onc.2008.20","article-title":"Structure\/function relationships underlying regulation of FOXO transcription factors","volume":"27","author":"Obsil","year":"2008","journal-title":"Oncogene"},{"key":"B33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41419-023-06177-1","article-title":"FOXO family isoforms","volume":"14","author":"Santos","year":"2023","journal-title":"Cel Death and Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm3507","article-title":"FOXOs: signalling integrators for homeostasis maintenance","volume":"14","author":"Eijkelenboom","year":"2013","journal-title":"Nat Rev Mol Cel Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"Akt, FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim Biophys Acta (Bba) - Mol Cel Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cvr\/cvs426","article-title":"FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival","volume":"97","author":"Puthanveetil","year":"2013","journal-title":"Cardiovasc Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.redox.2015.06.019","article-title":"Redox regulation of FoxO transcription factors","volume":"6","author":"Klotz","year":"2015","journal-title":"Redox Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"951597","DOI":"10.3389\/fcvm.2022.951597","article-title":"Perspectives for Forkhead box transcription factors in diabetic cardiomyopathy: their therapeutic potential and possible effects of salvianolic acids","volume":"9","author":"Han","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/circheartfailure.114.001457","article-title":"Activation of foxo1 by insulin resistance promotes cardiac dysfunction and \u03b2\u2013myosin heavy chain gene expression","volume":"8","author":"Qi","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/circulationaha.106.637124","article-title":"Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling","volume":"114","author":"Ni","year":"2006","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yjmcc.2014.06.006","article-title":"Deletion of FoxO1 leads to shortening of QRS by increasing Na+ channel activity through enhanced expression of both cardiac NaV1.5 and \u03b23 subunit","volume":"74","author":"Cai","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/circulationaha.106.632430","article-title":"Transcriptional genomics associates FOX transcription factors with human heart failure","volume":"114","author":"Hannenhalli","year":"2006","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/circresaha.117.312052","article-title":"Suppression of activated FOXO transcription factors in the heart prolongs survival in a mouse model of laminopathies","volume":"122","author":"Auguste","year":"2018","journal-title":"Circ Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"H479","DOI":"10.1152\/ajpheart.00191.2017","article-title":"FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression","volume":"313","author":"Gopal","year":"2017","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.celrep.2021.108935","article-title":"FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity","volume":"35","author":"Gopal","year":"2021","journal-title":"Cel Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1111\/jcmm.15418","article-title":"FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes","volume":"24","author":"Yan","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.freeradbiomed.2011.04.009","article-title":"Cardiac triglyceride accumulation following acute lipid excess occurs through activation of a FoxO1\u2013iNOS\u2013CD36 pathway","volume":"51","author":"Puthanveetil","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","article-title":"Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice","volume":"55","author":"Pham","year":"2023","journal-title":"Exp and Mol Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbrc.2021.01.038","article-title":"Prostaglandin E receptor subtype 4 protects against diabetic cardiomyopathy by modulating cardiac fatty acid metabolism via FOXO1\/CD36 signalling","volume":"548","author":"Ying","year":"2021","journal-title":"Biochem Biophysical Res Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/circresaha.120.316738","article-title":"KLF5 is induced by FOXO1 and causes oxidative stress and diabetic cardiomyopathy","volume":"128","author":"Kyriazis","year":"2021","journal-title":"Circ Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1111\/jcmm.15725","article-title":"Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1\u2010Foxo1 and PI3K\u2010Akt signalling pathways","volume":"24","author":"Ren","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3892\/ijmm.2018.3832","article-title":"Opening of mitoKATP improves cardiac function and inhibits apoptosis via the AKT-Foxo1 signaling pathway in diabetic cardiomyopathy","volume":"42","author":"Duan","year":"2018","journal-title":"Int J Mol Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"8624","DOI":"10.7150\/thno.48561","article-title":"Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/jcmm.12312","article-title":"Resveratrol\u2010enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice","volume":"18","author":"Wang","year":"2014","journal-title":"J Cell Mol Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.2337\/diabetes.53.9.2366","article-title":"Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob\/ob mouse hearts","volume":"53","author":"Mazumder","year":"2004","journal-title":"Diabetes"},{"key":"B57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","article-title":"Loss of metabolic flexibility in the failing heart","volume":"5","author":"Karwi","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"11155","DOI":"10.1074\/jbc.m110.217349","article-title":"Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response","volume":"286","author":"Chambers","year":"2011","journal-title":"J Biol Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.jacc.2008.07.062","article-title":"Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus","volume":"52","author":"Rijzewijk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1152\/ajpendo.00419.2001","article-title":"Insulin induces the translocation of the fatty acid transporter FAT\/CD36 to the plasma membrane","volume":"282","author":"Luiken","year":"2002","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","article-title":"Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential","volume":"172","author":"Faria","year":"2017","journal-title":"Pharmacol and Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1681\/asn.2008050514","article-title":"RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes","volume":"20","author":"Coughlan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.bbrc.2009.02.132","article-title":"Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells","volume":"381","author":"Li","year":"2009","journal-title":"Biochem Biophysical Res Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1038\/ncomms4315","article-title":"A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response","volume":"5","author":"Shao","year":"2014","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fendo.2019.00202","article-title":"Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart","volume":"10","author":"Ding","year":"2019","journal-title":"Front Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12265-020-09984-5","article-title":"Exendin-4 protects against myocardial ischemia-reperfusion injury by upregulation of SIRT1 and SIRT3 and activation of AMPK","volume":"14","author":"Eid","year":"2020","journal-title":"J Cardiovasc Translational Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/939751","article-title":"Role of forkhead transcription factors in diabetes-induced oxidative stress","volume":"2012","author":"Ponugoti","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/onc.2008.25","article-title":"The role of FoxO in the regulation of metabolism","volume":"27","author":"Gross","year":"2008","journal-title":"Oncogene"},{"key":"B69","doi-asserted-by":"publisher","first-page":"20517","DOI":"10.1073\/pnas.0610290104","article-title":"FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases","volume":"104","author":"Ni","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.2337\/db15-0244","article-title":"Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo","volume":"64","author":"Bharath","year":"2015","journal-title":"Diabetes"},{"key":"B71","doi-asserted-by":"publisher","first-page":"28319","DOI":"10.1074\/jbc.m109.024406","article-title":"FoxO transcription factors promote autophagy in cardiomyocytes","volume":"284","author":"Sengupta","year":"2009","journal-title":"J Biol Chem"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1161\/circresaha.110.227371","article-title":"Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes","volume":"107","author":"Hariharan","year":"2010","journal-title":"Circ Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ncb2069","article-title":"Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity","volume":"12","author":"Zhao","year":"2010","journal-title":"Nat Cel Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e51632","DOI":"10.1371\/journal.pone.0051632","article-title":"Autophagy plays an essential role in mediating regression of hypertrophy during unloading of the heart","volume":"8","author":"Hariharan","year":"2013","journal-title":"PLoS ONE"},{"key":"B75","doi-asserted-by":"publisher","first-page":"H1470","DOI":"10.1152\/ajpheart.00838.2020","article-title":"FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K","volume":"320","author":"Weeks","year":"2021","journal-title":"Am J Physiology-Heart Circulatory Physiol"}],"container-title":["Journal of Pharmacy &amp; Pharmaceutical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2024.13193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T04:11:28Z","timestamp":1723608688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2024.13193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":75,"alternative-id":["10.3389\/jpps.2024.13193"],"URL":"https:\/\/doi.org\/10.3389\/jpps.2024.13193","relation":{},"ISSN":["1482-1826"],"issn-type":[{"type":"electronic","value":"1482-1826"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"article-number":"13193"}}